Resume Printable PDF
EDUCATION AND TRAINING
2002–2007 Ph.D. Molecular Pharmacology and Toxicology (major), Drug Metabolism and Pharmacokinetics (minor), Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada. Thesis title: Molecular Mechanisms Involved in the Modulation of Aryl Hydrocarbon Receptor-Regulated Genes by Mercury, Lead, and Copper.
1990–1995 B.Sc. of Pharmaceutical Sciences (Class Honor), College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
2008– now Assistant Professor, Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
2002–2006 Teaching Assistant, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
2000–2002 Drug Information Pharmacist, Drug and Poison Information Center, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
1996–2002 Teaching Assistant, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
AWARDS AND HONORS
2006–2007 University of Alberta Dissertation Fellowship.
2006 Top 25 hottest article within the Chemico-Biological Interactions journal.
2006 Dr. L. Chatten Award for the best podium presentation, faculty of Pharmacy Research Day.
2005 Award of Excellence for Outstanding Poster Presentation, the Canadian Society for Pharmaceutical Sciences 8th symposium, Toronto, ON, Canada.
2005 Faculty of Pharmacy Research Day Best Graduate Student Poster Presentation.
2005 University of Alberta Graduate Student Association’s Professional Development Award, University of Alberta.
2004–2006 Health Research Foundation / Canada Institute for Health Research Graduate Research Scholarship in Pharmacy.
2004–2006 Walter H. Johns Graduate Fellowship, University of Alberta.
2004–2005 Queen Elizabeth II Graduate Scholarship, University of Alberta.
2004 Mary Louise Imrie Graduate Student Award, Faculty of Graduate Studies and Research, University of Alberta.
2004 Society of Toxicology Graduate Student Travel Award, SOT 43rd annual meeting, Baltimore, Maryland, USA.
2003–2004 Mike Wolowyk Graduate Scholarship, University of Alberta.
2004 – 2007 Society of Toxicology (SOT)
2003 – 2007 Canadian Society for Pharmaceutical Sciences
2006 – 2007 Society of Toxicology of Canada
· Extensive teaching experience at the undergraduate and graduate levels such as Pharmacy Home Health Care (PHARM 483), Pharmacy Practice (PHARM 302), Pharmacokinetics (PHARM 415), Toxicology (PHARM 403), and Nutrition (PHARM 327), and for graduate students, such as Advance Drug Metabolism (PHARM 630) and Analytical Techniques and Instrumentation (PHARM 573).
· Supervising pharmacy summer students.
· Establishing a webpage for El-kadi’s laboratory http://www.ualberta.ca/~aelkadi/dmp
RESEARCH AND SCHOLARLY ACT IVITIES
Investigating the molecular mechanisms involved in the modulation of aryl hydrocarbon receptor (AhR)-regulated genes by environmental pollutants and contaminants, such heavy metals, at the activity, protein and mRNA levels in hepatic cell lines. Heavy metals such as mercury, lead and copper are of health concern because of the possibility of environmental contamination by both natural and man-made sources, and the impact that such contamination can have on human health.
Heavy metals and AhR ligands are common environmental co-contaminants of hazardous waste sites and are co-released from sources such as fossil fuel combustion and municipal waste incineration and as components of tobacco. Both AhR ligands and heavy metals are ranked highly as the most hazardous xenobiotics in the environment, prepared by Canadian Environmental Protection Act and the Agency for Toxic Substances and Disease Registry and the Environmental Protection Agency. The toxicity of AhR ligands is based on their bioactivation by CYP1A1 to yield mutagenic and carcinogenic intermediates. Environmental co-contamination of heavy metals with AhR ligands could affect the mutagenicity and carcinogenicity of these compounds.
My long-term objectives are to 1) understand the potential interaction between heavy metals and AhR ligands which are common in the environment on the regulation of AhR-regulated genes, and 2) investigate the effects of AhR ligand/metal mixtures on AhR ligands mutagenicity and carcinogenicity.
o Real-time polymerase chain reaction (RT-PCR), reverse-transcription polymerase chain reaction, and Northern blot analysis.
o Western blot analysis for determination of protein expression.
o Electrophoretic mobility shift assay (EMSA) for determination of DNA-protein interactions.
o Measurement of total CYP450s and cellular heme content.
o Measurement of catalytic activities of several enzymes, such as CYP1A1, 1A2, 1B1, NQO1, GST, GSTA1, using specific substrates.
o Determination of oxidative stress markers such as mitochondrial reactive oxygen species using DCF assay, lipid peroxidation, and heme oxygenase expression, NF-κB, and AP-1.
o MTT assay for determination of cytotoxicity.
o Luciferase reporter gene activity.
o Cell culture techniques for different cell lines, such as human hepatoma HepG2 cells, murine hepatoma Hepa 1c1c7 cells, AhR-knockout hepatoma C12 cells, ARNT-knockout hepatoma C4 cells, and rat cardiomyocyte H9C2 cells.
o Radiation and Safety Course, University of Alberta, Canada (2002).
o NON-MEM Population Pharmacokinetics Workshop, University of Alberta, Canada (2007).
Research activities (Reviewing Manuscripts)
o Molecular Pharmacology manuscript entitled “RXRalpha Regulates the Expression of Glutathion S-transferase Genes and Modulates Acetaminophen-Glutathione Conjugation in mouse liver “
o Journal of Pharmacy and Pharmaceutical Sciences manuscript entitled “Protective effect of Licorice Water Extract against Cadmium-induced Toxicity in Rats”.
1. Korashy HM, El-Kadi AO, (2008): The p38 MAPK inhibitor SB203580 is a novel aryl hydrocarbon receptor lignad (Submitted).
2. Korashy HM, El-Kadi AO, (2008): NF-κB and AP-1 are key signaling pathways in the modulation of NAD(P)H: quinone oxidoreductase 1 gene by mercury, lead, and copper. J Biochem Mol Toxicol (In press).
3. El-Kadi AO, Korashy HM, Sebert JM, Bend JR, (2008): Modulation of glutathione S-transferase Ya and NAD(P)H:quinone oxidoreductase in mouse hepatoma Hepa 1c1c7 cells by bilirubin and Arsenite. J Biochem Mol Toxicol (In press).
4. Korashy HM, El-Kadi AO, (2008): The role of redox-sensitive transcription factors NF-κB and AP-1 in the modulation of the Cyp1a1 gene by mercury, lead, and copper. Free Radic Biol Med. 44, 795-806.
5. Korashy HM, El-Kadi AO, (2008): Modulation of TCDD-mediated induction of cytochrome P450 1A1 by mercury, lead, and copper in human HepG2 cell line. Toxicol In Vitro 22, 154-8.
6. Korashy HM, Brocks DR, and El-Kadi AO, (2007): Induction of the NAD(P)H:quinone oxidoreductase 1 by ketoconazole and itraconazole: a mechanism of cancer chemoprotection. Cancer Lett. 258,135-43.
7. Korashy HM, Shayeganpour A, Brocks DR, and El-Kadi AO, (2007): Induction of Cytochrome P450 1A1 by the Antifungal Drugs, Ketoconazole and Itraconazole but not Fluconazole. Toxicol Sci 97, 32-43.
8. Korashy HM, El-Kadi AO, (2006). The role of aryl hydrocarbon receptor and the reactive oxygen species in the modulation of Glutathion transferase by heavy metals in murine hepatoma cell lines. Chem Biol Interact 162, 237-48.
9. Korashy HM, El-Kadi AO, (2006): The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab Reviews 38, 1-40.
10. Korashy HM, El-Kadi AO (2006): Transcriptional regulation of the NAD(P)H:quinone oxidoreductase 1 and glutathione S-transferase Ya genes by mercury, lead, and copper. Drug Metab Dispos 34, 152-165.
11. Korashy HM, El-Kadi AO, (2005): Regulatory mechanisms modulating the expression of cytochrome P450 1a1 gene by heavy metals. Toxicol Sci 88, 39-51.
12. Korashy HM, El-Kadi AO (2004): Differential effects of mercury, lead, and copper on the constitutive and inducible expression of the aryl hydrocarbon receptor-regulated genes in cultured Hepa 1c1c7 cells. Toxicology 201, 53-72.
13. Elbekai RH, Korashy HM, Wills K, Gharavi N, El-Kadi AO, (2004): Benzo[a]pyrene, b-Naphthoflavone, 3-Methylcholanthrene induce Reactive Oxygen Species by Aryl Hydrocarbon receptor pathway. Free Radical Res 38, 1191-120.
14. Elbekai RH, Korashy HM, El-Kadi AO, (2004): The effects of liver diseases on the drug metabolizing enzymes. Curr Drug Metab 5, 157-67.
15. Korashy HM, Elbekai RH, El-Kadi AO, (2004): The effects of renal diseases on the regulation and expression of renal and hepatic drug metabolizing enzymes: a review. Xenobiotica 34, 1-29.
16. Al-Arifi MN, Gubara OG, Korashy HM, (1997) Drug Information Centers in Saudi Arabia: Evaluation of Community Pharmacists’ Services in Riyadh City. Saudi Pharm J 5, 83-189.
17. Shayeganpour A, Korashy HM, Patel J, El-Kadi AO, and Brocks DR (2007): The effect of hyperlipidemia on the hepatic metabolism of amiodarone to desethylamiodarone in rat. AAPS Annual meeting, November 9-15, 2007. San Diego, USA.
18. Korashy HM, El-Kadi AO, (2007): The role of redox-sensitive transcription factors AP-1 and NF-kB on the modulation of Cyp1a1 by Hg2+, Pb2+, and Cu2+. International Congress of Toxicology Meeting, July 15-19, 2007, Montreal, Canada.
19. Korashy HM and El-kadi AO, Induction of the Cytochrome P450 1A1 by the Antifungal Drugs. A Novel Mechanism of Cytotoxicity. (Podium). Faculty of Pharmacy Research Day, October 21 2006, Edmonton, Canada.
20. Korashy HM, Shayeganpour A, Brocks DR, and El-kadi AO, A novel mechanism of inducing the carcinogen-activating xenobiotic metabolizing enzyme cytochrome P450 1A1 by the antifungal drugs. Association of Faculties of Pharmacy of Canada 63rd Annual Conference June 2-4, 2006, Edmonton, Canada.
21. Korashy HM, El-kadi AO, Heavy metals regulate the NAD(P)H:quinone oxidoreductase 1 (Nqo1) gene expression through both AhR- and Nrf2-mediated transcriptional mechanisms. Society of Toxicology 45th Annual Meeting, March 5–9, 2006, San Diego, USA.
22. Korashy HM, El-Kadi AO, The transcriptional regulation of the NAD(P)H:quinone oxidoreductase 1 (Nqo1) gene by heavy metals. Pharmacy Research Day (2005), Faculty of Pharmacy and Pharmaceutical Sciences, Edmonton, Canada.
23. Korashy HM, El-Kadi AO, Transcriptional and post-transcriptional regulation of cytochrome P450 1a1 (Cyp1a1) by heavy metals. The Canadian Society for Pharmaceutical Sciences 8th annual symposium, May 30-June 1, 2005, Toronto, Canada.
24. Korashy HM, El-Kadi AO, Regulatory Mechanisms Modulating the Expression of Cyp1a1 Gene by Mercury, (podium). Faculty of Pharmacy Seminar, Feb. 2005, Edmonton, Canada.
25. Korashy HM, El-Kadi AO, Regulatory mechanisms modulating the expression of CYP1A1, QOR, and GST Ya genes by heavy metals. Pharmacy Research Day (2004), Faculty of Pharmacy and Pharmaceutical Sciences, Edmonton, Canada.
26. Korashy HM, El-Kadi AO, Differential effects of heavy metals on the regulation of aryl hydrocarbon receptor-regulated genes. Society of Toxicology Meeting (2004), Baltimore, USA.
27. Korashy HM, El-Kadi AO, Modulation of AHR-regulated genes by heavy metals. Pharmacy Research Day (2003), Faculty of Pharmacy and Pharmaceutical Sciences, Edmonton, Canada.
28. Korashy HM, Pharmacokinetics and Prescribing in Elderly. Saudi Pharmaceutical Society, Continuing Education Program (1996), Riyadh, Saudi Arabia.